Introduction Elranatamab-BCMM is a humanized bispecific antibody that binds B-cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells, redirecting cytotoxic activity against multiple myeloma cells (1). In phase 2 MagnetisMM-3, subcutaneous step-up dosing followed by weekly and then biweekly schedules achieved deep responses with
534 Reached
Pancytopenia, a rare presentation of hyperthyroidism
830 Reached2 Comments
Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1007 Reached2 Comments
Treatment of Recurrent Adult Medulloblastoma
2602 Reached1 Comments4 Likes
Positive Murphy’s Sign in Pericardial Hematoma from a Right Atrial Tear
359 Reached1 Comments2 Likes